Sugi Predict

Sugi Predict / Compounds / SCHEMBL3209712

SCHEMBL3209712

SCHEMBL3209712

Cc1sc2c(c1C)C(c1ccc(N)cc1)=N[C@@H](CC(=O)O)c1nnc(C)n1-2

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 0.82
▸ DNER Q8NFT8 2/20 0.72
▸ BRDT Q58F21 5/20 0.68
▸ BRD2 P25440 6/20 0.68
▸ ADORA3 P0DMS8 1/20 0.67
▸ TSPO P30536 1/20 0.67
▸ BRD3 Q15059 3/20 0.64
▸ CREBBP Q92793 2/20 0.64
▸ HDAC3 O15379 1/20 0.64
▸ JAK2 O60674 1/20 0.64
▸ BRD1 O95696 1/20 0.64
▸ CCL2 P13500 1/20 0.64
▸ HDAC4 P56524 1/20 0.64
▸ EP300 Q09472 1/20 0.64
▸ HDAC1 Q13547 1/20 0.64
▸ HDAC7 Q8WUI4 1/20 0.64
▸ HDAC2 Q92769 1/20 0.64
▸ HDAC10 Q969S8 1/20 0.64
▸ HDAC11 Q96DB2 1/20 0.64
▸ HDAC8 Q9BY41 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23801145 0.99 BRD4 (0.81) BRD4DNERBRDTBRD2ADORA3
SCHEMBL12228129 0.92 BRD4 (0.85) BRD4DNERBRDTBRD2ADORA3
SCHEMBL31548657 0.91 BRD4 (0.84) BRD4DNERBRDTBRD2ADORA3
SCHEMBL18484183 0.91 BRD4 (0.83) BRD4DNERBRDTBRD2ADORA3
SCHEMBL25092048 0.91 BRD4 (0.83) BRD4DNERBRDTBRD2ADORA3
SCHEMBL23252528 0.90 BRD4 (0.68) BRD4DNERBRDTBRD2ADORA3
SCHEMBL23801110 0.90 BRD4 (0.82) BRD4DNERBRDTBRD2ADORA3
SCHEMBL20463257 0.90 BRD4 (0.82) BRD4DNERBRDTBRD2ADORA3
SCHEMBL881274 0.90 BRD4 (1.00) BRD4DNERBRDTBRD2ADORA3
SCHEMBL7480681 0.90 BRD4 (1.00) BRD4DNERBRDTBRD2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124491-A1 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. 2024-04-18 — — US disclosed
EP-3849987-B1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER HOFFMANN LA ROCHE (CH) 2024-04-17 — — EP disclosed
EP-4342543-A2 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER F. Hoffmann-La Roche AG (CH) 2024-03-27 — — EP disclosed
EP-4274583-A2 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2023-11-15 — — EP disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 — — US disclosed
WO-2022150555-A2 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2022-07-14 — — WO disclosed
WO-2022150555-A2 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2022-07-14 — — WO disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 — — US disclosed
US-20210221821-A1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER GENENTECH, INC. (US) 2021-07-22 — — US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 — — EP disclosed
EP-1887008-B1 THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2021-04-21 — — EP disclosed
WO-2018066545-A1 HETEROCYCLIC COMPOUND 公益財団法人ヒューマンサイエンス振興財団 2018-04-12 — — WO disclosed
US-20100041643-A1 THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-02-18 — — US disclosed
EP-1887008-A1 THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124491-A1 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA ATXN2, ATXN2L, CDR2 BRD4 742/4885DNER 3272/4885BRDT 132/4885
US-20210221821-A1 TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3, 2-F][1, 2, 4]TRIAZOLO[4, 3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER BRD4, BRD3, BRD2 BRD4 1/4885DNER 1036/4885BRDT 6/4885
US-20100041643-A1 THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF ICOS, CD4, CD2 BRD4 265/4885DNER 3109/4885BRDT 159/4885
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB BRD4 2/4885DNER 780/4885BRDT 9/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB BRD4 2/4885DNER 690/4885BRDT 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.